0000899866-18-000037.txt : 20180208
0000899866-18-000037.hdr.sgml : 20180208
20180208191624
ACCESSION NUMBER: 0000899866-18-000037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180206
FILED AS OF DATE: 20180208
DATE AS OF CHANGE: 20180208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moriarty John B
CENTRAL INDEX KEY: 0001564621
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27756
FILM NUMBER: 18587124
MAIL ADDRESS:
STREET 1: ALEXION PHARMACEUTICALS
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000899866
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133648318
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 COLLEGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 2032722596
MAIL ADDRESS:
STREET 1: 100 COLLEGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
wf-form4_151813537006905.xml
FORM 4
X0306
4
2018-02-06
0
0000899866
ALEXION PHARMACEUTICALS INC
ALXN
0001564621
Moriarty John B
C/O ALEXION PHARMACEUTICALS, INC
100 COLLEGE STREET
NEW HAVEN
CT
06510
0
1
0
0
EVP & General Counsel
Common Stock, par value $.0001 per share
2018-02-06
4
A
0
21489
0
A
71400
D
Common Stock, par value $.0001 per share
2018-02-06
4
A
0
6500
0
A
77900
D
Common Stock, par value $.0001 per share
2018-02-08
4
S
0
2163
115.70
D
75737
D
Common Stock, par value $.0001 per share
2018-02-08
4
S
0
1200
115.70
D
74537
D
On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 21,489 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary.
On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 6,500 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary.
This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $115.20 - $116.20. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.25 - $117.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
/s/ Michael Greco, Attorney-in-Fact for John B. Moriarty
2018-02-08